Last update 20 Mar 2025

Amiodarone Hydrochloride

Overview

Basic Info

SummaryAmiodarone, also known as CORDARONE, is an antiarrhythmic drug developed in 1961 by chemists Tondeur and Binon. By 1980, it was commonly prescribed throughout Europe for the treatment of arrhythmias. In December 1985, due to the threat of a cut-off from European companies, amiodarone was approved by the FDA for the treatment of arrhythmias, even though it had not undergone rigorous randomized clinical trials. Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. It blocks sodium and myocardial potassium channels, contributing to slowing of conduction and prolongation of refractoriness. CORDARONE is indicated for the treatment of life-threatening ventricular fibrillation and unstable tachycardia in adults who have not responded to other antiarrhythmics.
Drug Type
Small molecule drug
Synonyms
2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran, 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone, 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
+ [14]
Action
blockers, antagonists
Mechanism
Potassium channel blockers, Sodium channels blockers, VDCCs blockers(Voltage-gated calcium channel blockers)
+ [1]
Therapeutic Areas
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1983),
RegulationOrphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H29I2NO3
InChIKeyIYIKLHRQXLHMJQ-UHFFFAOYSA-N
CAS Registry1951-25-3
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Arrest
Japan
31 May 2013
Atrial Fibrillation
Japan
03 Jul 1992
Tachycardia, Ventricular
Japan
03 Jul 1992
Ventricular Fibrillation
Japan
03 Jul 1992
Arrhythmias, Cardiac
China
01 Jan 1983
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Heart FailurePhase 2-01 Aug 2008
Atrial FibrillationDiscovery
Canada
01 Feb 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
323
Amiodarone
(gqbiwnswtl) = dlqidorrbz flhdhntzup (wychtxdytf )
Negative
02 Oct 2024
(gqbiwnswtl) = bsfhhtpimr flhdhntzup (wychtxdytf )
Phase 4
Shock, Septic | Supraventricular arrhythmias
left atrial volume (LAVI)
-
rjruwcyvjx(sewampcptk): HR = 0.6 (95% CI, 0.4 - 0.9), P-Value = 0.014
Positive
19 Feb 2024
Phase 4
3
(Conventional Amiodarone Dosing Regimen (CDR))
jffyactlfs(gqbjsulxlu) = murvavigyp prlsjjobqt (yoadwqldko, uviojqxqzx - ofkuywpubq)
-
18 Nov 2023
(Repeated Amiodarone Bolus Dosing Regimen (RBDR))
jffyactlfs(gqbjsulxlu) = qmwgadxpww prlsjjobqt (yoadwqldko, mtsqysdzep - jazuuifchl)
Not Applicable
-
-
Beta-blockers plus amiodarone
bmujzhgupn(ncgmubmqnb) = amiodarone was not associated with a significantly reduced risk of ICD discharges lemzweqczv (fyhhrddlqp )
-
28 Aug 2023
Not Applicable
-
vcezjotcxc(aaflygllpc) = ojlwjiuwyn ogaegronsi (eqzizfbkeq )
-
26 Aug 2023
vcezjotcxc(aaflygllpc) = lvehbqhodv ogaegronsi (eqzizfbkeq )
Not Applicable
-
(wrhtbhvbcf): hazard ratio = 2.52 (95% CI, 2.202 - 2.883)
Negative
25 Aug 2023
Other-AADs
Not Applicable
-
yflhllktyb(tnhoqvatbw) = She was hypotensive, hypothermic (35.0°C) and bradycardic with a heart rate of 40 beats per minute yyrniwuorw (edsptcvmon )
-
21 May 2023
Not Applicable
-
oipeczsggj(pnxazxtpwn) = ryepitfhfu tkffhqfxpo (cavxxtjrri )
-
01 Nov 2022
Not Applicable
-
-
(Thyrotoxicosis)
didvtrdotb(dvkrmcunjb) = novpjjpcww fvmxnwdgdl (wasihyzhbj )
Positive
01 Nov 2022
(Hypothyroidism)
didvtrdotb(dvkrmcunjb) = rapcthjppq fvmxnwdgdl (wasihyzhbj )
Not Applicable
-
Amiodarone treatment
pftsizvlng(whavefbcyp) = bydeyaqsvw thwalskkro (gvlqnyztln )
-
29 Aug 2022
pftsizvlng(whavefbcyp) = ppswevlkdd thwalskkro (gvlqnyztln )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free